Veradermics to discuss Phase 3 ‘304’ topline results on call
Veradermics announced it will host a conference call and live webcast on 19 October 2026 at 8:00 am ET to review Part A topline results from its randomized, double-blind, placebo-controlled phase 3 study 304 evaluating VDPHL01 in 536 males with mild-to-moderate pattern hair loss. A replay will be av
<p>Veradermics announced it will host a conference call and live webcast on 19 October 2026 at 8:00 am ET to review Part A topline results from its randomized, double-blind, placebo-controlled phase 3 study 304 evaluating VDPHL01 in 536 males with mild-to-moderate pattern hair loss. A replay will be av</p>